Back to Journals » Clinical Ophthalmology » Volume 5

Nonselective ß-blocker propranolol for orbital and periorbital hemangiomas in infants: a new first-line of treatment?

Authors El Essawy R, Galal R, Abdelbaki S

Published 18 November 2011 Volume 2011:5 Pages 1639—1644

DOI https://doi.org/10.2147/OPTH.S24141

Review by Single-blind

Peer reviewer comments 4


Rania El-Essawy1, Rascha Galal2, Sameh Abdelbaki1
1Department of Ophthalmology, 2Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt

Purpose: To determine the effectiveness and possible side effects of using propranolol for the treatment of orbital and periorbital infantile hemangiomas.
Methods: Infants with periorbital or orbital hemangiomas who had not received either local or systemic corticosteroids were recruited. The changes in tumor size, color, and texture, and any side effects of the drug were recorded.
Results: Fifteen infants with a mean age of 8.13 ± 4.7 months were treated according to the set protocol. A change in the color and texture of the hemangioma occurred in the first week following treatment. Mean duration of treatment was 7.67 ± 3.96 months. The size of hemangiomas decreased from a mean of 2.4 ± 0.9 cm to a mean of 1.6 ± 1.0 cm 3 months after treatment (P = 0.001). One patient had to stop the drug because of peripheral vascular ischemia. Another case had the dose reduced to control a mild hyperglycemia. Serious side effects were not observed. A single case of tumor regrowth (8.3%) was recorded.
Conclusion: Treatment of 1–2 mg/kg/day propranolol proved to be effective and associated with minimal side effects. It is likely to replace steroids as the first-line of treatment of hemangiomas in infants.

Keywords: orbital and periorbital hemangioma, ß-blockers, propranolol, corticosteroids, adrenal suppression

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]